Annie E. Wishna, M.D.

Professional Background

Dr. Wishna received her BA in College of Arts & Sciences from the University of Pennsylvania and her MD from Washington University School of Medicine in St. Louis, MO. She completed her internship at Weiss Memorial Hospital at the University of Chicago and her ophthalmology residency at the New York Eye and Ear Infirmary. She was also a Clinical Instructor at the New York Eye and Ear Infirmary before entering into private practice, first at the Eye Institute of New York and then at Grin Eye Care in Olathe. She joined the Department of Ophthalmology at the University of Kansas in December 2017 where she is currently a Clinical Associate Professor. She has been the Residency Program Director since January 2021. She has been selected for inclusion in Castle Connolly and Kansas City Magazine Top Doctors and Exceptional Women in Medicine. In 2025, Dr. Wishna was recognized with the American Academy of Ophthalmology's Secretariat Award for her contributions to the field.
Dr. Wishna sees diagnosing and treating eye disease and performing vision-saving surgeries as the most critical part of her job but believes the best part of patient care is making a personal connection. By really getting to know her patients, she is able to tailor their care to best meet their specific needs.
Her surgical focus is cataract surgery. Residents are often with her in surgery and she is a skilled and effective educator. Patients are sent to KUMC from across the state for ophthalmic trauma emergencies.

• BA, Biology, University of Pennsylvania , Philidelphia, PA
• MD, Ophthalmology, Washington University School of Medicine, St. Louis, MO
• Internship, Transitional Year, Weiss Memorial Hospital - University of Chicago, Chicago, IL
• Residency, Ophthalmology, New York Eye and Ear Infirmary, New York, NY

• DEA, Drug Enforcement Agency
• KBHA, Kansas Board of Healing Arts
• MBRHA, Missouri Board of Registration for the Healing Arts
• MD, Arizona Medical Board
• Ophthalmology, American Board of Ophthalmology

• American Academy of Ophthalmology, Committee for Resident Education, Member, 2025 - Present
• American Academy of Ophthalmology, Resident Surgical Anxiety Committee for Resident Education Sub-group, Committee Member, 2024 - Present
• Association of University Professors of Ophthalmology, Straatsma Award for Excellence in Resident Education Committee , Member, 2023 - 2026
• Women in Ophthalmology, Academic Interest Committee, Member, 2023 - Present
• Alpha Omega Alpha Honor Medical Society, Member, 2021 - Present
• Kansas Medical Society, Member, 2020 - Present
• Kansas Society of Eye Physicians and Surgeons, Legislative Working Group, Member, 2020 - 2021

---

Research

Overview

Dr. Wishna plays a ​role in several National Cancer Institute studies, ​monitoring for ophthalmic side effects of novel cancer treatments. Dr. Wishna has also done research on how eye conditions can manifest differently in women. She founded the Sustainability Ambassadors, a group of medical students dedicated to reducing the carbon footprint of ophthalmic surgery. The group ​was awarded a Green Grant from the American Academy of Ophthalmology in 2026 to support their efforts.

• A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer, none
• A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Choloangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy, none
• A Phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, none
• A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications, none
• A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma, none
• A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression versus Ipilimuab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma, none
• A randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer’s disease dementia, none
• A Randomized, Open-label, Phase 2 Study of Denintuzumab Mafodotin (SGN CD19A) Plus rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy versus RICE in the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) who are Candidates for Autologous Stem Cell Transplant, none
• A randomized, phase 2 trial of Intermittent versus continuous dosing of dabrafenib (NSC-763760) AND Trametinib (NSC-63093)in BRAFV600E/K mutant melanoma, none
• A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1), none
• A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4, none

• Berenbom, A, Milman, T, Finger, P., T. 2008. FIT biopsy for conjunctival squamous cell carcinoma with extensive intraocular invasion.. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 246 (3), 467-9
• Banitt, M, Berenbom, A, Shah, M, Buxton, D, Milman, T. 2008. A case of polymicrobial keratitis violating an intact lens capsule.. Cornea, 27 (9), 1057-61
• Wishna, Anne, Hurtig, Amanda, Templeton, Kim. 2019. Eye conditions in Women, Gender and the Genome. Gender and the Genome, 4 (1-12), 1-12. https://doi.org/10.1177/2470289720907105 |
• Alon, U., S, Berenbom, A. 2000. Idiopathic hypercalciuria of childhood: 4- to 11-year outcome.. Pediatric nephrology (Berlin, Germany), 14 (10-11), 1011-5
• Berenbom, A, Davila, R., M, Lin, H., S, Harbour, J., W. 2007. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.. Eye (London, England), 21 (9), 1198-201